Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis - Top-Institutions - MDSpire

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

In topline results from Lilly’s ADorable-1 trial, pediatric patients aged 6 months to 18 years had higher rates of skin clearance and itch improvement vs placebo, according to a press release from Eli Lilly and Company.

  • By

  • Kerri Miller

  • March 17, 2026

  • 4 min

Share

Top Institutions in Dermatology

Brief introduction explaining scope and methodology.

  • #1

    National Institute of Allergy and Infectious Diseases (NIAID), NIH
    National Institute of Allergy and Infectious Diseases (NIAID), NIH

    Bethesda, MD

    Key Differentiators

    • Pediatric Dermatology
    • Immunology
    • Clinical Trials

  • #2

    Children’s Hospital of Philadelphia (CHOP)
    Children’s Hospital of Philadelphia (CHOP)

    Philadelphia, PA

    Key Differentiators

    • Pediatric Dermatology
    • Clinical Research

  • #3

    Stanford University School of Medicine
    Stanford University School of Medicine

    Stanford, CA

    Key Differentiators

    • Dermatology
    • Pediatric Dermatology
    • Immunology

  • #4

    Massachusetts General Hospital (MGH) Dermatology
    Massachusetts General Hospital (MGH) Dermatology

    Boston, MA

    Key Differentiators

    • Dermatology
    • Pediatric Dermatology
    • Clinical Trials

  • #5

    University of California, San Francisco (UCSF) Medical Center
    University of California, San Francisco (UCSF) Medical Center

    San Francisco, CA

    Key Differentiators

    • Pediatric Dermatology
    • Immunodermatology

Original Source(s)

Lebrikizumab Meets Phase 3 End Points in Pediatric Atopic Dermatitis

  • by Kerri Miller

  • March 17, 2026

Related Content

Combination Therapy Shows Potential in Psoriasis, Obesity

Researchers assess whether adding tirzepatide to ixekizumab affects skin and weight outcomes in adults with moderate to severe plaque psoriasis.

Paradoxical inflammatory switches during biologic therapy: a mechanistic framework, clinical algorithm, and pediatric illustrations

AOPT Plus Collagen May Ease Rosacea

Randomized trial suggests better short-term outcomes and lower recurrence at 24 weeks.